MariTide is being studied for the treatment of obesity and Type 2 diabetes and demonstrated weight loss at 52 weeks.

The acquisition will grant Roche full ownership over a pipeline of allogeneic CAR-T therapy candidates, including two ...

California-based BridgeBio has secured US FDA approval for its lead candidate drug, acoramidis (brand name Attruby) for ...

Despite disappointing results in the genetic neurodegenerative disorder, the drug shows potential for treating obesity.

We’re thrilled to announce that we have migrated BioPharmaReporter to a new platform. Our expert coverage of the sector won’t ...